| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222244 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2022
(1 year, 5 months ago) | |
| US7973031 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2028
(4 years from now) | |
| US8575146 | NOVARTIS | Pharmaceutical uses of staurosporine derivatives |
Dec, 2030
(6 years from now) | |
Rydapt is owned by Novartis.
Rydapt contains Midostaurin.
Rydapt has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Rydapt are:
- US8222244
Rydapt was authorised for market use on 28 April, 2017.
Rydapt is available in capsule;oral dosage forms.
Rydapt can be used as treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl).
Drug patent challenges can be filed against Rydapt from 28 April, 2021.
The generics of Rydapt are possible to be released after 02 December, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-140) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-141) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE) | Apr 28, 2024 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
Drugs and Companies using MIDOSTAURIN ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolid...
Dosage: CAPSULE;ORAL
RYDAPT family patents
